chr3-36996633-C-T
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM2PM5PP3_StrongPP5_Very_Strong
The NM_000249.4(MLH1):c.131C>T(p.Ser44Phe) variant causes a missense change. The variant allele was found at a frequency of 0.000000684 in 1,460,950 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S44A) has been classified as Benign.
Frequency
Consequence
NM_000249.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MLH1 | NM_000249.4 | c.131C>T | p.Ser44Phe | missense_variant | 2/19 | ENST00000231790.8 | NP_000240.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MLH1 | ENST00000231790.8 | c.131C>T | p.Ser44Phe | missense_variant | 2/19 | 1 | NM_000249.4 | ENSP00000231790.3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome AF: 6.84e-7 AC: 1AN: 1460950Hom.: 0 Cov.: 30 AF XY: 0.00 AC XY: 0AN XY: 726846
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Colorectal cancer, hereditary nonpolyposis, type 2 Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Mar 17, 1994 | - - |
Lynch syndrome Pathogenic:1
Pathogenic, reviewed by expert panel | research | International Society for Gastrointestinal Hereditary Tumours (InSiGHT) | Sep 05, 2013 | Abrogated function, >2 MSI-H tumours, co-segregation with disease & MAF 0.00. Multifactorial likelihood analysis posterior probability >0.99 - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics and Genomics, Karolinska University Hospital | Sep 16, 2014 | - - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Aug 29, 2022 | The p.S44F pathogenic mutation (also known as c.131C>T), located in coding exon 2 of the MLH1 gene, results from a C to T substitution at nucleotide position 131. The serine at codon 44 is replaced by phenylalanine, an amino acid with highly dissimilar properties. This well-characterized alteration has been previously described in a family with Lynch syndrome and was found to segregate with disease in an early study linking MLH1 to Lynch syndrome (Bronner CE et al. Nature 1994 Mar; 368(6468):258-61). Numerous functional assays evaluating MLH1-PMS2 interaction levels, MLH1 protein expression levels, spontaneous mutation rates, β-galactosidase activity, and dominant mutator deficiency have all demonstrated pathogenic effects of the p.S44F alteration (Pang Q et al. Mol. Cell. Biol. 1997 Aug; 17(8):4465-73; Guerrette S et al. J. Biol. Chem. 1999 Mar; 274(10):6336-41; Ellison AR et al. Hum. Mol. Genet. 2001 Sep; 10(18):1889-900; Kondo E et al. Cancer Res. 2003 Jun; 63(12):3302-8; Takahashi M et al. Cancer Res. 2007 May; 67(10):4595-604). One study identified this alteration in two unrelated Swedish families with Lynch syndrome that shared the same founding haplotype; a subsequent study identified this alteration in more Swedish Lynch syndrome families (Tannergård P et al. Cancer Res. 1995 Dec; 55(24):6092-6; Lagerstedt-Robinson K et al. Oncol Rep. 2016 Nov;36(5):2823-2835). This alteration has been classified as pathogenic using the following lines of evidence: in silico prediction models, segregation with disease, clinical phenotype including tumor characteristics, mutation co-occurrence, and functional studies (Thompson BA et al. Hum. Mutat. 2013 Jan;34:200-9; Thompson BA et al. Nat. Genet. 2014 Feb;46:107-15; available at [www.insight-group.org/variants/classifications/]). Based on the available evidence, p.S44F is classified as a pathogenic mutation. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at